Intactis Bio joins the Biocomputing industry, which seeks to deliver lower-energy, cost-efficient computing capacity driven ...
Recent discussion of artificial intelligence in intelligence analysis has consistently framed the technology as a means of accelerating an existing process. The intelligence cycle (collection, ...
Dean Ball, a former White House AI policy adviser, is joining OpenAI (OPENAI) to lead a new team created to shape frontier AI policy within the company. "I am pleased and honored to announce that, on ...
Richard Socher has been a major figure in AI for some time, best known for founding the early chatbot startup You.com and, before that, his work on ImageNet. Now he’s joining the current generation of ...
Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...
Ineffable Intelligence, a British AI lab founded a mere few months ago by former DeepMind researcher David Silver, has raised $1.1 billion in funding at a valuation of $5.1 billion to join the race ...
That architectural choice matters because OpenViking is not trying to remove semantic retrieval. It is trying to constrain and structure it. The project’s retrieval pipeline first uses vector ...
Smart Fork Detection solves the "context loss" problem in AI-assisted development by maintaining a searchable vector database of all your Claude Code sessions. When you need to work on a similar task ...
Recursive Language Models aim to break the usual trade off between context length, accuracy and cost in large language models. Instead of forcing a model to read a giant prompt in one pass, RLMs treat ...
The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. 10 stocks we like better ...
Hosted on MSN
Is Recursion Pharmaceuticals a Millionaire Maker?
Recursion Pharmaceuticals developed a promising artificial intelligence (AI) platform for drug discovery and development. The company's clinical-stage pipeline is just the tip of the iceberg of its ...
Welcome everybody to Recursion's Earnings Call. I'm Chris Gibson, Co-Founder and CEO, and I'm excited to take you through Recursions 2024, 2025 and the time ahead. So with that we'll jump into the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results